Is Vertex Pharmaceuticals Stock a Good Investment?
Vertex Pharmaceuticals Investment Advice | VRTX |
- Examine Vertex Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Vertex Pharmaceuticals' leadership team and their track record. Good management can help Vertex Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Vertex Pharmaceuticals' business and its evolving consumer preferences.
- Compare Vertex Pharmaceuticals' performance and market position to its competitors. Analyze how Vertex Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Vertex Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Vertex Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Vertex Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Vertex Pharmaceuticals is a good investment.
Sell | Buy |
Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very Small | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Vertex Pharmaceuticals Stock
Researching Vertex Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 96.0% of the company outstanding shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 1.22. Vertex Pharmaceuticals recorded a loss per share of 1.92. The entity had not issued any dividends in recent years. The firm had 2:1 split on the 24th of August 2000.
To determine if Vertex Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Vertex Pharmaceuticals' research are outlined below:
| Vertex Pharmaceuticals generated a negative expected return over the last 90 days | |
| Vertex Pharmaceuticals is unlikely to experience financial distress in the next 2 years | |
| Over 96.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from theatlantic.com: What If Opioids Didnt Have to Be Addictive |
Vertex Pharmaceuticals Quarterly Good Will |
|
Vertex Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Vertex Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Vertex Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 5th of February 2024 Upcoming Quarterly Report | View | |
| 6th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 5th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Vertex Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Vertex Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2013-01-29 | 2012-12-31 | -0.08 | -0.09 | -0.01 | 12 | ||
2016-10-25 | 2016-09-30 | 0.18 | 0.16 | -0.02 | 11 | ||
2000-02-16 | 1999-12-31 | 0.01 | 0.03 | 0.02 | 200 | ||
1999-07-27 | 1999-06-30 | -0.19 | -0.21 | -0.02 | 10 | ||
1998-02-23 | 1997-12-31 | -0.15 | -0.13 | 0.02 | 13 | ||
1997-04-22 | 1997-03-31 | -0.15 | -0.13 | 0.02 | 13 | ||
2016-07-27 | 2016-06-30 | 0.21 | 0.24 | 0.03 | 14 | ||
1999-10-27 | 1999-09-30 | -0.25 | -0.28 | -0.03 | 12 |
Know Vertex Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Vertex Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Vertex Pharmaceuticals backward and forwards among themselves. Vertex Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Vertex Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Wellington Management Company Llp | 2024-06-30 | 4.1 M | Amundi | 2024-06-30 | 3.5 M | Norges Bank | 2024-06-30 | 3.4 M | Loomis, Sayles & Company Lp | 2024-06-30 | 3.1 M | Massachusetts Financial Services Company | 2024-09-30 | 2.9 M | Bank Of America Corp | 2024-06-30 | 2.6 M | Ubs Asset Mgmt Americas Inc | 2024-09-30 | 2.4 M | Legal & General Group Plc | 2024-06-30 | 2.4 M | Hhg Plc | 2024-06-30 | 2.4 M | Capital World Investors | 2024-09-30 | 26.8 M | Vanguard Group Inc | 2024-09-30 | 23.2 M |
Vertex Pharmaceuticals' market capitalization trends
The company currently falls under 'Mega-Cap' category with a current market capitalization of 120.56 B.Market Cap |
|
Vertex Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.17 | 0.18 | |
| Return On Capital Employed | 0.22 | 0.24 | |
| Return On Assets | 0.16 | 0.17 | |
| Return On Equity | 0.21 | 0.22 |
Determining Vertex Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Vertex Pharmaceuticals is a good buy. For example, gross profit margin measures Vertex Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Vertex Pharmaceuticals' profitability and make more informed investment decisions.
Vertex Pharmaceuticals' Earnings Breakdown by Geography
Please note, the imprecision that can be found in Vertex Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Vertex Pharmaceuticals. Check Vertex Pharmaceuticals' Beneish M Score to see the likelihood of Vertex Pharmaceuticals' management manipulating its earnings.
Evaluate Vertex Pharmaceuticals' management efficiency
Vertex Pharmaceuticals has return on total asset (ROA) of 0.1205 % which means that it generated a profit of $0.1205 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0298) %, meaning that it created substantial loss on money invested by shareholders. Vertex Pharmaceuticals' management efficiency ratios could be used to measure how well Vertex Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.18 in 2024. Return On Capital Employed is likely to rise to 0.24 in 2024. At this time, Vertex Pharmaceuticals' Return On Assets are fairly stable compared to the past year.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 68.22 | 71.63 | |
| Tangible Book Value Per Share | 60.74 | 63.78 | |
| Enterprise Value Over EBITDA | 20.69 | 21.73 | |
| Price Book Value Ratio | 5.96 | 7.46 | |
| Enterprise Value Multiple | 20.69 | 21.73 | |
| Price Fair Value | 5.96 | 7.46 | |
| Enterprise Value | 15.8 B | 8.3 B |
Understanding the operational decisions made by Vertex Pharmaceuticals management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Beta 0.394 |
Basic technical analysis of Vertex Stock
As of the 30th of November, Vertex Pharmaceuticals has the Risk Adjusted Performance of (0.02), variance of 2.97, and Coefficient Of Variation of (3,212). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Vertex Pharmaceuticals, as well as the relationship between them.Vertex Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vertex Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vertex Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Vertex Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bozic Carmen over two months ago Disposition of 2812 shares by Bozic Carmen of Vertex Pharmaceuticals at 420.58 subject to Rule 16b-3 | ||
Charles Wagner over a year ago Sale by Charles Wagner of 3000 shares of Vertex Pharmaceuticals | ||
Charles Wagner over a year ago Payment of 2707 shares by Charles Wagner of Vertex Pharmaceuticals subject to Rule 16b-3 |
Vertex Pharmaceuticals' Outstanding Corporate Bonds
Vertex Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Vertex Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Vertex bonds can be classified according to their maturity, which is the date when Vertex Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| VERTICAL HOLDCO GMBH Corp BondUS92537VAA89 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| VERTICAL U S Corp BondUS92537RAA77 | View | |
| US92535UAB08 Corp BondUS92535UAB08 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Understand Vertex Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Vertex Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.07) | |||
| Mean Deviation | 1.29 | |||
| Coefficient Of Variation | (3,212) | |||
| Standard Deviation | 1.72 | |||
| Variance | 2.97 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.17) | |||
| Total Risk Alpha | (0.35) | |||
| Treynor Ratio | (0.08) | |||
| Maximum Drawdown | 9.8 | |||
| Value At Risk | (3.15) | |||
| Potential Upside | 2.36 | |||
| Skewness | (0.04) | |||
| Kurtosis | 1.39 |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.07) | |||
| Mean Deviation | 1.29 | |||
| Coefficient Of Variation | (3,212) | |||
| Standard Deviation | 1.72 | |||
| Variance | 2.97 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.17) | |||
| Total Risk Alpha | (0.35) | |||
| Treynor Ratio | (0.08) | |||
| Maximum Drawdown | 9.8 | |||
| Value At Risk | (3.15) | |||
| Potential Upside | 2.36 | |||
| Skewness | (0.04) | |||
| Kurtosis | 1.39 |
Consider Vertex Pharmaceuticals' intraday indicators
Vertex Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Vertex Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 13761.02 | |||
| Daily Balance Of Power | 0.4245 | |||
| Rate Of Daily Change | 1.01 | |||
| Day Median Price | 466.73 | |||
| Day Typical Price | 467.19 | |||
| Price Action Indicator | 3.19 | |||
| Period Momentum Indicator | 3.57 | |||
| Relative Strength Index | 73.63 |
Vertex Pharmaceuticals Corporate Filings
F4 | 19th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 5th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 4th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Vertex Stock media impact
Far too much social signal, news, headlines, and media speculation about Vertex Pharmaceuticals that are available to investors today. That information is available publicly through Vertex media outlets and privately through word of mouth or via Vertex internal channels. However, regardless of the origin, that massive amount of Vertex data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Vertex Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Vertex Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Vertex Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Vertex Pharmaceuticals alpha.
Vertex Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Vertex Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Vertex Pharmaceuticals Historical Investor Sentiment
Investor biases related to Vertex Pharmaceuticals' public news can be used to forecast risks associated with an investment in Vertex. The trend in average sentiment can be used to explain how an investor holding Vertex can time the market purely based on public headlines and social activities around Vertex Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Vertex Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Vertex Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Vertex Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Vertex Pharmaceuticals.
Vertex Pharmaceuticals Corporate Management
| Jonathan JD | Executive Officer | Profile | |
| Stephanie Franklin | Senior Officer | Profile | |
| Mike Tirozzi | SVP Officer | Profile | |
| Damian Esq | Chief VP | Profile | |
| Ourania Tatsis | Ex Officer | Profile |
Additional Tools for Vertex Stock Analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.